HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System
The system’s design emphasizes user friendliness and portability while aligning with the growing trend toward remote patient monitoring and telemedicine. HeartBeam to initiate commercial launch upon FDA clearance of 12-lead ECG synthesis software, anticipated later this year. For decades, the traditional 12-lead electrocardiogram (“ECG”) has been the gold standard in cardiac diagnostics, including arrhythmia assessment, offering a comprehensive assessment of the heart's electrical activity. However, traditional 12-lead ECG systems often come with limitations such as cumbersome setups and restricted accessibility. HeartBeam (NASDAQ: BEAT) is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart's…
